Endocrine treatment for breast cancer
The endocrine treatment of breast cancer is aimed at inhibiting tumour cell growth by reducing levels of estrogen in the body or inhibiting estrogen. Endocrine treatment of breast cancer, including surgical, therapeutic and pharmaceutical aspects, usually does not cause obesity. The procedure is usually hysterectomy, and the ovarian irradiation, which is not associated with obesity and generally does not result in obesity. Drug treatments include hormone receptors, such as fluoris; aromatic enzyme inhibitors, such as palladium, anacara, Iximetan, etc.; estrogen competitive inhibitors, such as mosaics; ovarian decompressants, such as Goserrin, Light Pryrin and Triprin, which are reasonably used under the direction of a physician and usually do not result in obesity, but may result in cholesterol rise, glycerine triester rise and osteoporosis. Over-upping and feeding of breast cancer patients during endocrine treatment can cause obesity, but it has nothing to do with the treatment itself. If the patient is obese, the diet can be adjusted to increase exercise and weight control. Patients are advised to actively treat breast cancer under the guidance of a doctor, to have a reasonable diet in the course of breast cancer endocrinic treatment, to maintain a calm mind, not to eat spicy and irritating food, and to avoid smoking and drinking. With regard to endocrinology treatment for breast cancer, it is primarily the LuminalA type or part of the LuminalB type, which is ERPR positive, that is treated with endocrinology. Endocrine treatment is an anti-estrogen, pregnancy hormone, like triphenylamide used in clinically, and aromatic enzyme inhibitor type AI. Such drugs are suitable for use in patients ‘ menopause, and ERPR receptors have positive expression. There’s another type of drug that’s similar to the hormonal hormonal release of cedars, called LHRH. In clinically, Gosherrin, Twistrin, and Light Pryrin, these drugs are known as drugs. The fact that the endocrinology treatment for breast cancer is extensive or informative, and that the use of these three types of drugs, including the time spent, requires adequate communication between doctors and patients.
